179 related articles for article (PubMed ID: 10361552)
1. Prostate-specific antigen and other markers of therapeutic response.
Carducci MA; DeWeese TL; Nelson JB
Urol Clin North Am; 1999 May; 26(2):291-302, viii. PubMed ID: 10361552
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
Lieberman R
Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.
Payne H; Cornford P
Urol Oncol; 2011; 29(6):593-601. PubMed ID: 20060331
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.
Drachenberg DE; Elgamal AA; Rowbotham R; Peterson M; Murphy GP
Prostate; 1999 Oct; 41(2):127-33. PubMed ID: 10477909
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.
Collette L; Burzykowski T; Schröder FH
Eur J Cancer; 2006 Jul; 42(10):1344-50. PubMed ID: 16730974
[TBL] [Abstract][Full Text] [Related]
6. Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate.
Kramer G; Steiner GE; Madersbacher S; Stulnig T; Lang T; Marberger M
J Urol; 1997 Oct; 158(4):1446-51. PubMed ID: 9302140
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?
Schröder FH; Kranse R; Barbet N; Hop WC; Kandra A; Lassus M
Prostate; 2000 Feb; 42(2):107-15. PubMed ID: 10617867
[TBL] [Abstract][Full Text] [Related]
8. Response criteria in prostatic carcinoma.
Dawson NA
Semin Oncol; 1999 Apr; 26(2):174-84. PubMed ID: 10597728
[TBL] [Abstract][Full Text] [Related]
9. Prognostic indicators in hormone refractory prostate cancer.
George DJ; Kantoff PW
Urol Clin North Am; 1999 May; 26(2):303-10, viii. PubMed ID: 10361553
[TBL] [Abstract][Full Text] [Related]
10. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Brachlow J; Kälin M; Randazzo M; Förster B; John H
Praxis (Bern 1994); 2016 Aug; 105(16):971-7. PubMed ID: 27524169
[No Abstract] [Full Text] [Related]
12. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.
Collette L
Eur Urol; 2008 Jan; 53(1):6-9. PubMed ID: 17764823
[No Abstract] [Full Text] [Related]
14. [The role of PSA in diagnosis of prostate cancer and its recurrence].
Vergho DC; Heine K; Wolff JM
Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
[TBL] [Abstract][Full Text] [Related]
15. [Treatment options for hormone-refractory prostate cancer].
Heidenreich A; Ohlmann CH
Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of prostate cancer: concepts and strategies.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovitch L; Malone WA; Crowell JA; Sigman CC
Eur Urol; 1999; 35(5-6):342-50. PubMed ID: 10325487
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen.
Ornstein DK; Pruthi RS
Expert Opin Pharmacother; 2000 Dec; 1(7):1399-411. PubMed ID: 11249473
[TBL] [Abstract][Full Text] [Related]
18. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
[TBL] [Abstract][Full Text] [Related]
19. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
20. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
